Patents by Inventor Nil Dizdar Segrell
Nil Dizdar Segrell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230330015Abstract: An aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), comprises at least 5 mg/ml dissolved levodopa and has a pH in the range of 3.0 to 8.5. The solution is provided by mixing a) an aqueous stock solution comprising levodopa and having a pH of less than 2.8 at 25° C., and b) an aqueous buffering solution having a pH of at least 4.0 at 25° C. for increasing the pH of the stock solution. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the CNS shortly after mixing of the aqueous stock solution and the aqueous buffering solution. A kit for administration of the aqueous pharmaceutical solution includes a bag comprising two parts and a removable or perforable barrier between the two parts.Type: ApplicationFiled: February 28, 2023Publication date: October 19, 2023Inventors: Elias ERIKSSON, Nil DIZDAR SEGRELL, Mats EHRNEBO, Leif BRING
-
Patent number: 11633353Abstract: The invention provides an aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), the solution comprising at least 5 mg/ml dissolved levodopa, and having a pH in the range of 3.0 to 8.5. Said solution is provided by mixing a) an aqueous stock solution comprising levodopa, said stock solution having a pH of less than 2.8 at 25° C. and b) an aqueous buffering solution, for increasing the pH of said stock solution, said buffering solution having a pH of at least 4.0 at 25° C. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the central nervous system (CNS) shortly after mixing of the aqueous stock solution and the aqueous buffering solution. Furthermore, the invention provides a kit for administration of aqueous pharmaceutical solutions to subjects suffering from diseases of the central nervous system (CNS).Type: GrantFiled: June 5, 2018Date of Patent: April 25, 2023Assignee: DIZLIN PHARMACEUTICALS ABInventors: Elias Eriksson, Nil Dizdar Segrell, Mats Ehrnebo, Leif Bring
-
Publication number: 20210378954Abstract: The invention provides an aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), the solution comprising at least 5 mg/ml dissolved levodopa, and having a pH in the range of 3.0 to 8.5. Said solution is provided by mixing a) au aqueous stock solution comprising levodopa, said stock solution having a of less than 2.8 at 25° C. and b) an aqueous buffering solution, for increasing the pH of said stock solution, said buffering solution having a pH of at least 4.0 at 25° C. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the central nervous system (CNS) shortly after mixing of the aqueous stock solution and the aqueous buffering solution. Furthermore, the invention provides a kit for administration of aqueous pharmaceutical solutions to subjects suffering from diseases of the central nervous system (CNS).Type: ApplicationFiled: June 5, 2018Publication date: December 9, 2021Inventors: Elias ERIKSSON, Nil DIZDAR SEGRELL, Mats EHRNEBO, Leif BRING
-
Publication number: 20210212945Abstract: The invention provides an aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), the solution comprising at least 5 mg/ml dissolved levodopa, and having a pH in the range of 3.0 to 8.5. Said solution is provided by mixing a) au aqueous stock solution comprising levodopa, said stock solution having a of less than 2.8 at 25° C. and b) an aqueous buffering solution, for increasing the pH of said stock solution, said buffering solution having a pH of at least 4.0 at 25° C. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the central nervous system (CNS) shortly after mixing of the aqueous stock solution and the aqueous buffering solution. Furthermore, the invention provides a kit for administration of aqueous pharmaceutical solutions to subjects suffering from diseases of the central nervous system (CNS).Type: ApplicationFiled: June 5, 2018Publication date: July 15, 2021Inventors: Elias ERIKSSON, Nil DIZDAR SEGRELL, Mats EHRNEBO, Leif BRING
-
Publication number: 20200146986Abstract: The invention provides an aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), the solution comprising at least 5 mg/ml dissolved levodopa, and having a pH in the range of 3.0 to 8.5. Said solution is provided by mixing a) an aqueous stock solution comprising levodopa, said stock solution having a pH of less than 2.8 at 25° C. and b) an aqueous buffering solution, for increasing the pH of said stock solution, said buffering solution having a pH of at least 4.0 at 25° C. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the central nervous system (CNS) shortly after mixing of the aqueous stock solution and the aqueous buffering solution. Furthermore, the invention provides a kit for administration of aqueous pharmaceutical solutions to subjects suffering from diseases of the central nervous system (CNS).Type: ApplicationFiled: June 5, 2018Publication date: May 14, 2020Inventors: Elias ERIKSSON, Nil DIZDAR SEGRELL, Mats EHRNEBO, Leif BRING
-
Patent number: 9248113Abstract: A method of eliminating or significantly decreasing shifts between dyskinesia and bradykinesia in a patient suffering from an advanced stage of Parkinson's Disease comprises for a predetermined time period intravenously, subcutaneously or intrathekally administering to the patient by continuous infusion a stable and therapeutically acceptable solution comprising at least 5 mg/ml of Levodopa.Type: GrantFiled: April 14, 2014Date of Patent: February 2, 2016Assignee: Dizlin Medical Design ABInventor: Nil Dizdar Segrell
-
Publication number: 20140221489Abstract: A method of eliminating or significantly decreasing shifts between dyskinesia and bradykinesia in a patient suffering from an advanced stage of Parkinson's Disease comprises for a predetermined time period intravenously, subcutaneously or intrathekally administering to the patient by continuous infusion a stable and therapeutically acceptable solution comprising at least 5 mg/ml of Levodopa.Type: ApplicationFiled: April 14, 2014Publication date: August 7, 2014Applicant: Dizlin Medical Design ABInventor: Nil Dizdar Segrell
-
Patent number: 8735382Abstract: An infusion or injection solution of Levodopa containing at least 10 mg/mL of Levodopa, or at least 5 mg/mL of Levodopa together with at least 0.5 mg/mL of at least one inhibitor of a Levodopa-metabolising enzyme is disclosed. The solution further contains a buffer, a physiologically acceptable sugar, such as glucose, a physiologically acceptable acid, such as hydrochloric acid, and optionally a stabilizer, and has a pH of lower than or equal to 6. There are also described a disposable syringe containing an infusion or injection solution of Levodopa, optionally together with a Levodopa-metabolising enzyme, and an infusion pump cassette containing an infusion or injection solution of Levodopa optionally together with a Levodopa-metabolising enzyme.Type: GrantFiled: August 12, 2011Date of Patent: May 27, 2014Assignee: Dizlin Medical Design ABInventor: Nil Dizdar Segrell
-
Publication number: 20110294889Abstract: An infusion or injection solution of Levodopa containing at least 10 mg/mL of Levodopa, or at least 5 mg/mL of Levodopa together with at least 0.5 mg/mL of at least one inhibitor of a Levodopa-metabolising enzyme is disclosed. The solution further contains a buffer, a physiologically acceptable sugar, such as glucose, a physiologically acceptable acid, such as hydrochloric acid, and optionally a stabilizer, and has a pH of lower than or equal to 6. There are also described a disposable syringe containing an infusion or injection solution of Levodopa, optionally together with a Levodopa-metabolising enzyme, and an infusion pump cassette containing an infusion or injection solution of Levodopa optionally together with a Levodopa-metabolising enzyme.Type: ApplicationFiled: August 12, 2011Publication date: December 1, 2011Inventor: Nil Dizdar Segrell
-
Publication number: 20080255235Abstract: An infusion or injection solution of Levodopa containing at least 10 mg/mL of Levodopa, or at least 5 mg/mL of Levodopa together with at least 0.5 mg/mL of at least one inhibitor of a Levodopa-metabolising enzyme is disclosed. The solution further contains a buffer, a physiologically acceptable sugar, such as glucose, a physiologically acceptable acid, such as hydrochloric acid, and optionally a stabilizer, and has a pH of lower than or equal to 6. There are also described a disposable syringe containing an infusion or injection solution of Levodopa, optionally together with a Levodopa-metabolising enzyme, and an infusion pump cassette containing an infusion or injection solution of Levodopa optionally together with a Levodopa-metabolising enzyme.Type: ApplicationFiled: July 8, 2005Publication date: October 16, 2008Applicant: Dizlin Medical Design ABInventor: Nil Dizdar Segrell